Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1622 1623 1626 1629
This examiner grants 76% of resolved cases
Karen Cheng is an examiner in Tech Center 1600 and Art Unit 1621. The examiner has 692 resolved cases. The data shows an allowance rate of 76.3 percent for these cases. This 76.3 percent rate provides a baseline for applicants to evaluate the probability of success when their applications are assigned to this examiner.
The interview lift for this examiner is 26.7 percent. This 26.7 percent lift is a comparison to the allowance rate, suggesting that direct communication is a factor in the prosecution process. Practitioners can use this figure to evaluate the impact of conducting an interview, as it correlates with an increased probability of reaching an allowance compared to the 76.3 percent baseline.
The median days to allowance for Cheng is 772. This 772-day measure provides an expectation for the duration of the patent prosecution cycle. With 692 resolved cases, the examiner has a history that supports these metrics. The combination of the allowance rate and the 772-day median pendency helps in planning patent strategies for Art Unit 1621.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17635631 | ARYL AND PYRIDYL AMIDE PESTICIDES AND COMPOSITIONS THEREOF | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 17807292 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Final Rejection | AbbVie Inc. |
| 18008648 | PREPARATION METHOD OF ACRYLONITRILE DIMER | Non-Final OA | LG CHEM, LTD. |
| 18268673 | PESTICIDAL MIXTURES | Final Rejection | BASF SE |
| 17620103 | FUROSEMIDE ANALOGUES AND COMPOSITIONS AND USES THEREOF FOR TREATMENT OF ALZHEIMER'S DISEASE | Non-Final OA | UNIVERSITY HEALTH NETWORK |
| 18580788 | SUBSTITUTED HETERO-BICYCLOCOMPOUNDS AS SUBTYPE SELECTIVE NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | Final Rejection | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS |
| 17616586 | BROAD SPECTRUM ANTIVIRAL COMPOUNDS TARGETING THE SKI COMPLEX | Final Rejection | UNIVERSITY OF MARYLAND, BALTIMORE |
| 18700748 | TRPC6 INHIBITORY COMPOUNDS FOR TREATING SEPSIS | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18562243 | APT1 and APT2 Inhibitors and Uses Thereof | Non-Final OA | Cornell University |
| 18626187 | ANTIBIOTICS COMPRISING LPXH-TARGETING COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | Duke University |
| 18687190 | EP4 ANTAGONIST COMPOUND AS WELL AS SALT, POLYMORPH AND USE THEREOF | Non-Final OA | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy